Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Conceptus ( CPTS)

Company Profile: Conceptus develops, manufactures and markets the Essure permanent birth control system, an innovative and proprietary medical device for women.

Current Share Price: $13.81 (Jan. 4)

Potential Upside: 67% based on a price target of $23

Barrington's Take: Conceptus is the last of the six new additions to Barrington's Best Ideas List for 2011 as the company "offers investors an appealing long-term growth story and is trading at an attractive valuation, in our view." The firm notes the success of Conceptus' Essure permanent birth control solution, which has a five-year effectiveness rate of 99.74%.

"We believe Essure is the best device with the most cost effective, efficacious and safe solution on or near to market with improving fourth and fifth generation devices," Barrington wrote. "Essure has not had a pregnancy from its clinical trial after more than five years of follow-up."

-- Written by Robert Holmes in Boston.

>To contact the writer of this article, click here: Robert Holmes.

>To follow Robert Holmes on Twitter, go to http://twitter.com/RobTheStreet.

>To submit a news tip, send an email to: tips@thestreet.com.
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

If you liked this article you might like

Rebuilding Efforts From Hurricanes Harvey and Irma Make These 6 Stocks Must Buys

3 'Orphan Stocks' to Consider Adopting

Novartis AG, Sirius XM Radio, Coupa Software: 'Mad Money' Lightning Round

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)